V07: Need for isolation and other prophylactic or treatment measures
Excludes:
long-term (current) (prophylactic) use of certain specific drugs (V58.61-V58.69)
prophylactic organ removal (V50.41-V50.49)
V07.5 Use of agents affecting estrogen receptors and estrogen levels
Code first, if applicable:
malignant neoplasm of breast (174.0-174.9, 175.0-175.9)
malignant neoplasm of prostate (185)
Use additional code, if applicable, to identify:
estrogen receptor positive status (V86.0)
family history of breast cancer (V16.3)
genetic susceptibility to cancer (V84.01-V84.09)
personal history of breast cancer (V10.3)
personal history of prostate cancer (V10.46)
postmenopausal status (V49.81)
Excludes:
hormone replacement therapy (postmenopausal) (V07.4)
V07.51: Use of selective estrogen receptor modulators (SERMs)
Use of:
raloxifene (Evista)
tamoxifen (Nolvadex)
toremifene (Fareston)
V07.52: Use of aromatase inhibitors
Use of:
anastrozole (Arimidex)
exemestane (Aromasin)
letrozole (Femara)
V07.59: Use of other agents affecting estrogen receptors and estrogen levels
Use of:
estrogen receptor downregulators
fulvestrant (Faslodex)
gonadotropin-releasing hormone (GnRH) agonist
goserelin acetate (Zoladex)
leuprolide acetate (leuprorelin) (Lupron)
megestrol acetate (Megace)

Home